Department of Internal Medicine & Infectious Diseases, Bordeaux Hospital University, Avenue de Magellan, Pessac, 33604, France.
FHU ACRONIM, Bordeaux, 33000, France.
Immunotherapy. 2021 Dec;13(18):1491-1499. doi: 10.2217/imt-2020-0313. Epub 2021 Nov 8.
To describe the effects of a summertime pause (SP) in immunoglobulin replacement therapy (IgRT). We conducted a prospective single-center observational study, including 44 patients undergoing intravenous IgRT between May and June 2019 in a French teaching hospital. IgRT was interrupted in 23 patients from June to October. Patients who underwent an SP were older, more likely to have secondary immunodeficiency (SID) and received lower doses of immunoglobulin and more antibiotics during winter. Most patients who did not undergo an SP had severe primary immunodeficiency. The SP did not increase the risk of infection, improved the quality of life and reduced treatment costs. SP in IgRT is a safe practice and should be considered for patients with mild SID.
描述免疫球蛋白替代疗法（IgRT）中夏季暂停（SP）的效果。我们进行了一项前瞻性单中心观察性研究，纳入了 2019 年 5 月至 6 月在法国教学医院接受静脉内 IgRT 的 44 名患者。23 名患者的 IgRT 从 6 月至 10 月中断。接受 SP 的患者年龄更大，更有可能患有继发性免疫缺陷（SID），并且在冬季接受的免疫球蛋白剂量更低和更多的抗生素。大多数未接受 SP 的患者患有严重的原发性免疫缺陷。SP 并未增加感染风险，改善了生活质量并降低了治疗成本。IgRT 中的 SP 是一种安全的做法，应考虑用于轻度 SID 患者。
